Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the updated analysis of the KEYNOTE-426 trial (NCT02853331). This study evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). Pembrolizumab in combination with axitinib continued to demonstrate superior and durable antitumor activity versus sunitinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).